A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Phase 4

Terminated

Interventions: Combination Product: Abilify MyCite - Digital Medicine System
Drug: Aripiprazole or other oral antipsychotics

Brief Summary: The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls. In addition, secondary and exploratory objectives were to assess medication adherence, healthcare utilization and costs, and patient-reported outcomes.

Detailed Description: This was a phase 4, open-label, prospective, pragmatic clinical trial to assess the difference between all-cause hospitalizations in participants using Abilify MyCite (for Months 1-3, then prohibited for Months 4-6) versus virtual matched controls from baseline to Day 180. Virtual matched controls were to receive treatment as usual (that is, any product other than Abilify MyCite, which was oral aripiprazole or any other product). Eligible participants entered a screening period of up to 13 days. For participants enrolling into the study, those not on aripiprazole at screening used the screening period for conversion to aripiprazole from other antipsychotics. Virtual matched controls were not to be enrolled into the study, but identified from health insurance claims data and matched to the enrolled Abilify MyCite participants at the end of the study for analysis.

After the visit at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) could have been initiated per the joint decision of the participants with their study physician; participants in this second, optional interventional period were to have a visit at Day 360. During this second, optional interventional period, participants may have started and stopped Abilify MyCite as clinically indicated.

A parallel exploratory study that would utilize a different set of physicians and participants from the main study was planned; however, that study was never initiated.

Recruitment & Eligibility

Inclusion Criteria

Participants are actively enrolled in an Anthem-affiliated commercial, Medicaid, or Medicare health plan with medical and pharmacy benefits.
Participants must have a smartphone with data plan.
Participants currently prescribed aripiprazole, or appropriate for aripiprazole treatment.
Participants must have a current diagnosis of SCH, BP1, or MDD.

Exclusion Criteria

Any participant who participated in another clinical trial within 30 days of enrollment into the current study.
Females who are breast-feeding and/or who are pregnant at the time of study enrollment, or who plan to become pregnant during the study.
Participants who are currently being treated with a long-acting injectable antipsychotic.

Arm && Interventions

Group	Intervention	Description
Abilify MyCite	Abilify MyCite - Digital Medicine System	Participants received Abilify MyCite during Months 1-3. During Months 4-6 use of Abilify MyCite was to be prohibited. Thereafter, at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) could have been initiated per the joint decision of the participants with their study physician.
Abilify MyCite	Aripiprazole or other oral antipsychotics	Participants received Abilify MyCite during Months 1-3. During Months 4-6 use of Abilify MyCite was to be prohibited. Thereafter, at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) could have been initiated per the joint decision of the participants with their study physician.
Virtual Matched Controls	Aripiprazole or other oral antipsychotics	Virtual matched controls were to receive treatment as usual (that is, any product other than Abilify MyCite, which could have been oral aripiprazole or any other product) throughout the duration of the trial. Virtual matched controls were not to be enrolled into the study, but identified from health insurance claims data and matched to the enrolled Abilify MyCite participants at the end of the study for analysis.

Primary Outcome Measures

Name	Time	Method
Difference In The Number Of Participants With All-cause Hospitalizations For Participants Using Abilify MyCite Versus Virtual Matched Controls From Baseline To Day 180	Baseline through Day 180	This outcome measure describes the difference in all-cause hospitalizations (that is hospitalizations for any reason) between the number of participants using Abilify MyCite and those receiving treatment as usual (the virtual matched controls). Due to early study termination, efficacy data were not collected.

Secondary Outcome Measures

Name	Time	Method
Difference In The Number Of Participants With At Least 80% Proportion Of Days Covered (PDC) (With Antipsychotic Medication) For Participants Using Abilify MyCite Versus Virtual Matched Controls From Baseline To Day 180	Baseline through Day 180	This outcome measure describes the difference in the number of participants with at least 80% PDC (with antipsychotic medication) between those using Abilify MyCite and those receiving treatment as usual (the virtual matched controls). Due to early study termination, efficacy data were not collected.

Locations (5): Psychiatric Addiction Curative/PACT Atlanta LLC
🇺🇸
Decatur, Georgia, United States
Kolade Research Institute
🇺🇸
Las Vegas, Nevada, United States
Georgia Psychiatry and Sleep
🇺🇸
Smyrna, Georgia, United States
Siyan Clinical Research
🇺🇸
Santa Rosa, California, United States
Signature Research Associates, Inc.
🇺🇸
Fairlawn, Ohio, United States